GC
CALA

Grimes & Company’s Calithera Biosciences, Inc CALA Stock Holding History

Grimes & Company’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,754
Closed -$251K – 317
2021
Q3 		$251K Buy
5,754
+200
+4% +$8.63K 0.01% 260
2021
Q2 		$232K Buy
5,554
+538
+11% +$23.6K 0.01% 270
2021
Q1 		$243K Buy
5,016
+3,017
+151% +$176K 0.01% 251
2020
Q4 		$196K Buy
1,999
+234
+13% +$20.5K 0.01% 256
2020
Q3 		$122K Buy
1,765
+720
+69% +$62.8K 0.01% 240
2020
Q2 		$110K Sell
1,045
-220
-17% -$26.1K 0.01% 239
2020
Q1 		$112K Hold
1,265
– – 0.01% 216
2019
Q4 		$144K Buy
1,265
+250
+25% +$18.8K 0.01% 256
2019
Q3 		$63K Buy
+1,015
New +$81.3K ﹤0.01% 250

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Grimes & Company's CALA Position: Q4 2021 in Review

Grimes & Company sold out of Calithera Biosciences, Inc (CALA) in Q4 2021, closing a stake of 5,754 shares — an estimated $251K sold.

Grimes & Company first reported a position in CALA in Q3 2019 and held it in 9 quarters. The position peaked at $251K in Q3 2021. 55 funds tracked by Wall St. Rank hold CALA as of Q4 2021.

  • Grimes & Company reported no remaining Calithera Biosciences, Inc position as of Q4 2021 after selling out during the quarter.
  • Grimes & Company sold 5,754 Calithera Biosciences, Inc shares in Q4 2021, an estimated $251K.
  • Grimes & Company first reported a position in Calithera Biosciences, Inc in Q3 2019 and held it in 9 quarters.
  • Grimes & Company's Calithera Biosciences, Inc position peaked at $251K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q4 2021.

Based on Grimes & Company's 13F filing for Q4 2021, filed 1 Feb 2022.